COVID-19 convalescent plasma for B-cell depleted patients: a systematic review and individual patient data meta-analysis

COVID-19 convalescent plasma (CCP) obtained from recently recovered people is safe and effective against SARS-CoV-2. Currently available CCP is a “hybrid” product with antibodies from individuals who had both infection and vaccination (vaccine-boosted CCP). B-cell depleted patients are at risk of no...

Full description

Bibliographic Details

Published in:	Frontiers in Medicine
Main Authors:	Solomiia Zaremba, Daniele Focosi, Wyatt W. Pruter, Massimo Franchini, Diana B. Collantes Hoyos, Mario Cruciani, Alex J. Miller, Juan G. Ripoll, Arturo Casadevall, Sidna M. Tulledge-Scheitel, Nathalie Rufer, Thomas Hueso, Justin E. Juskewitch, Camille M. van Buskirk, Petros Ioannou, Francesco Lanza, Raymund R. Razonable, Ferenc Magyari, László Imre Pinczés, Ravindra Ganesh, Claudia M. Denkinger, Ryan T. Hurt, Maike Janssen, James R. Stubbs, Carsten Müller-Tidow, Jeffrey L. Winters, Karin Holm, Sameer A. Parikh, Gordana Simeunovic, Neil E. Kay, Bart J. Rijnders, Scott R. Wright, Nahema Issa, Hélène Chaussade, Rickey E. Carter, Darrell R. Schroeder, Jonathon W. Senefeld, Michael J. Joyner
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-10-01
Subjects:	convalescent plasma COVID-19 B-cell depletion anti-CD20 therapy immunodeficiency SARS-CoV-2
Online Access:	https://www.frontiersin.org/articles/10.3389/fmed.2025.1658593/full